Liver transplantation and hepatocellular carcinoma
β Scribed by Itsuo Yokoyama; Hiroshi Takagi
- Publisher
- John Wiley and Sons
- Year
- 1996
- Tongue
- English
- Weight
- 527 KB
- Volume
- 12
- Category
- Article
- ISSN
- 8756-0437
No coin nor oath required. For personal study only.
β¦ Synopsis
Liver transplantation for advanced hepatocellular carcinoma (HCC) continues to be a subject of debate mostly due to a uniformly high failure rate secondary to recurrence. However, accumulating experiences have enabled detailed analysis of the prognostic factors affecting patient outcome. Clinicopathological factors affecting survival have been reported to include tumor size, number, lobar distribution, vascular invasion, lymphnode metastasis, and histologic type such as fibrolamellar variant of HCC. Poor prognosis has been associated with advanced stage of the tumor, particularly pTNM stage IV. Many transplant centers now use a protocol of adjuvant chemotherapy with reasonable success, although experiences are limited. Better understanding in tumor biology, particularly of the role of immunosuppression affecting tumor growth, will provide further success in the treatment of HCC by liver transplantation.
π SIMILAR VOLUMES
Background: Liver transplantation for unresectable hepatocellular carcinoma yields disappointing results. Most cases recur within 2 years, often in the transplanted liver. Methods: A combination of neoadjuvant doxorubicin and orthotopic liver transplantation was used in 20 patients with unresectable
This study was partially supported by grants UBACYT M055 (Universidad de Buenos Aires) and PICT 06-124 (Agencia Nacional de PromocioΒ΄n Cien-tΔ±Β΄fica y TecnoloΒ΄gica).
## Key Points 1. Hepatic epithelioid hemangioendothelioma is a rare disease with a variable natural history; current data support liver transplantation for unresectable disease. 2. Anti-vascular endothelial cell growth factor therapy may change the approach to hepatic epithelioid hemangioendotheli